SCHEMBL6514249

SCHEMBL6514249

Cc1cc(CS(=O)(=O)O)cc(C)c1Oc1ccc2[nH]cc(S(=O)(=O)c3ccc(F)cc3)c2c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
HTT P42858 3/20 0.53
LMNA P02545 2/20 0.53
KDM4E B2RXH2 2/20 0.52
MAPT P10636 3/20 0.51
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
RXFP1 Q9HBX9 2/20 0.43
TP53 P04637 2/20 0.42
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
THRA P10827 5/20 0.40
THRB P10828 5/20 0.40
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
DUSP3 P51452 1/20 0.36
PTPN5 P54829 1/20 0.36
PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522239 0.92 MAPT (0.61) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6512092 0.91 MAPT (0.60) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6520440 0.90 SMN1; SMN2 (0.52) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6515790 0.90 MAPT (0.50) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6860428 0.90 MAPT (0.48) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6523435 0.89 MAPT (0.48) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6516325 0.89 SMN1; SMN2 (0.50) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6518542 0.89 SMN1; SMN2 (0.50) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6515940 0.88 SMN1; SMN2 (0.52) SMN1; SMN2HTTLMNAKDM4EMAPT
SCHEMBL6511343 0.87 SMN1; SMN2 (0.48) SMN1; SMN2HTTLMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 SMN1; SMN2 4749/4885HTT 399/4885LMNA 3113/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP SMN1; SMN2 4875/4885HTT 1524/4885LMNA 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.